CSPC PHARMA (01093.HK) has initiated a Phase II clinical trial in China of
SYS-6026 injection for treatment of HPV16/18‑related high-grade cervical
squamous intraepithelial lesions.
2026-07-22
CSPC PHARMA (01093.HK) has initiated a Phase II clinical trial in China of
SYS-6026 injection for treatment of HPV16/18‑related high-grade cervical
squamous intraepithelial lesions.